MedTrace Logo

Impact of Virtual Reality on the Quality of Life of Oncology Patients

NCT06485869 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-07-03

No results posted yet for this study

Summary

Anxiety, nausea and vomiting are common side effects in paediatric patients receiving chemotherapy. chemotherapy. New evidence supports the efficacy of immersive virtual reality in improving symptoms of anxiety and distress, including nausea and vomiting, in this vulnerable group. This research will evaluate the efficacy of virtual reality in managing anxiety, nausea and vomiting in cancer patients receiving their first line of chemotherapy and will also measure the quality of life of these patients and evaluate patient and nursing staff satisfaction

Conditions

Interventions

OTHER

Measure the improvement in quality of life

Improvment of quality of life is measured by the QLQ-C30 quality of life questionnaire

OTHER

Measure the level of satisfaction of patients and nursing staff

Patient satisfaction is measured using a five-point scale ranging from 1 = strongly disagree to 5 = strongly agree. Higher scores indicate higher levels of satisfaction.

OTHER

Measurement of anxiety and pain

Anxiety and pain is measured by Visual Analogue Scale (VAS). This measurement is complemented by physiological responses to anxiety, measured by heart rate and mean arterial blood pressure (HR and BP)

OTHER

Measurement of depressive state

Depressive State is measured by HAD score

OTHER

measuring fatigue levels

Fatigue levels is measured by Visual Analogue Scale (VAS).

OTHER

measurement of acute nausea and vomiting

acute nausea and vomiting is measured by MASCC Antiemesis Tool (MAT)

Sponsors & Collaborators

  • Central Hospital Saint Quentin

    lead OTHER_GOV

Principal Investigators

  • Frédérique Mm Roussel · CH SAINT-QUENTIN

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-01
Primary Completion
2026-08-29
Completion
2026-08-29

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06485869 on ClinicalTrials.gov